Navigation Links
VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
Date:10/29/2009

loan from Bay City Capital;
  • our ability to timely recruit and enroll patients in any future clinical trials;
  • our failure to obtain sufficient data from enrolled patients that can be used to evaluate VIA-2291, thereby impairing the validity or statistical significance of our clinical trials;
  • our ability to successfully complete our clinical trials of VIA-2291 on expected timetables and the outcomes of such clinical trials;
  • complexities in designing and implementing cardiometabolic clinical trials using surrogate endpoints in Phase 1 and Phase 2 clinical trials which may differ from the ultimate endpoints required for registration of a candidate drug;
  • the results of our clinical trials, including without limitation, with respect to the safety and efficacy of VIA-2291;
  • if the results of the ACS and CEA studies, upon further review and analysis, are revised, interpreted differently by regulatory authorities or negated by later stage clinical trials;
  • our ability to obtain necessary FDA approvals, including to initiate future clinical trials of VIA-2291;
  • our ability to successfully commercialize VIA-2291;
  • our ability to identify potential clinical candidates from the family of DGAT1 compounds licensed and move them into preclinical development;
  • our ability to obtain and protect our intellectual property related to our product candidates;
  • our potential for future growth and the development of our product pipeline, including the THR beta agonist candidate and the other compounds licensed from Roche;
  • our ability to obtain strategic opportunities to partner and collaborate with large biotechnology or pharmaceutical companies to further develop VIA-2291;
  • our ability to form and maintain collaborative relationships to develop and commercialize our product candidates;
  • general economic and business conditions; and
  • the other risks described under Item 1A "Risk
    '/>"/>

    • SOURCE VIA Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5

    Related medicine news :

    1. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
    2. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
    3. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
    4. DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America
    5. Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009
    6. Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
    7. Amira Pharmaceuticals to Present at Montgomery Healthcare Conference
    8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
    9. Onyx Pharmaceuticals to Host Investor Briefing Following ECCO/ESMO Oncology Congress
    10. Biostar Pharmaceuticals, Inc. to Present at the Maxim Group Growth Conference on September 29 at 2:00pm ET
    11. DUSA Pharmaceuticals to Present at the Maxim Group 3rd Annual Growth Conference

    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/30/2009)...swire/ -- HealthPlus of Michigan today announced t...ns designed for Medicare-eligible people looking f...s to quality health care. ,, HealthPlus Medica...Michigan, according to the "America,s Best Health ...p; World Report and the National Committee on Qual...
    (Date:11/30/2009)...PRNewswire-USNewswire/ -- In Massachusetts, approx...cared for at home, so the Alzheimer,s Association ...line during the holiday season. For most families,...erness and sharing, but for a family dealing with ...lled with special challenges, according to the exp...
    (Date:11/30/2009)...swire/ -- Kool Smiles received top honors for it...gnition as one of InfoWorld ,s Top 100 IT Proj...ark Blomquist, Kool Smiles built a Wyse-based thin...ealth records systems at 13 new dental offices acr...plete, Kool Smiles has implemented electronic heal...
    (Date:11/30/2009)...wswire/ -- Mary Rita Hyland, Assistant Vice Presid... (SSI) has been elected to the 2010 Board for the ... ,, Hyland has held a variety of leadership pos...01. She was initially charged with the development...and Business Continuity for SSI. She later develop...
    (Date:11/30/2009)...ant impact, CBO analysis understates the effect ,...-- The Blue Cross and Blue Shield Association (BC...estimate released today by the Congressional Budge... many economists, actuaries, and health policy exp...form bill would make coverage more expensive for m...
    Breaking Medicine News(10 mins):Health News:HealthPlus Launches New Medicare Advantage Plans 2Health News:HealthPlus Launches New Medicare Advantage Plans 3Health News:Alzheimer's Caregivers Face Holiday Stress 2Health News:Kool Smiles Named Among 2009 InfoWorld 100 2Health News:SSI Assistant Vice President Elected to WEDI Board 2Health News:CBO Confirms That Premiums Will Increase Under the Senate Healthcare Reform Bill 2
    ...ademy of Pediatrics has reported that all infants,...iven vitamin D to help prevent rickets, a potentia... grow straight and strong. While breast milk is th...nlight, a natural source of the vitamin D. All inf...
    ...udy by researchers at St Mary's Hospital, Manchest...se is an important factor in women under 30 with b...r 30 who had been diagnosed with breast cancer sho...e found to carry// mutations in the BRCA1 or BRCA2...
    ...patients with viral encephalitis by researchers at... condition could cause seriouys movement problems...th the condition, five of whom had West Nile viru...onus (sudden jerking), chorea (writhing) and balli...
    ... by researchers at the A & A Pain Institute in St ...reduction & Algology: the study of pain), have fo...gs dramatic relief to nerve pain caused by cancer...algesic drugs were not effective in relieving the ...
    ... by Ohio State University researchers has shown th... attack are not being managed appropriately. The ...rt attack victims have found that patients' own d...s found that anxiety levels varied from none to se...
    ...n Pharmaceutical Association has given out a list ...r pleasure trips to help continue safe use of pres...e informed: A schedule of the drugs that you are t...lp you adjust to changes in time zones and changes...
    Other Medicine News:
    (Date:11/30/2009)... , CLEVELAND, Nov. 30 /PRNewswire-FirstCall/ ...echnology and services company focused on global e...y, today announced that PFC Pharma Focus AG (PFC) ...ave the ability to contract for DATATRAK,s CRO par...Clinical(TM) product suite. In addition, PFC will...
    (Date:11/30/2009)... , BOTHELL, Wash., Nov. 30 /PRNewswire-Fir...nnounced today that on November 25, 2009, the NYSE...at it had accepted the Company,s plan to comply wi...er Section 1003(a)(iv) of the Exchange Company Gui...at the Company sustained losses which were so subs...
    (Date:11/30/2009)... , MELVILLE, N.Y., Nov. 30 /PRNewswire-First... largest provider of health care products and serv...mpany,s Executive Vice President and Chief Financi...vestor Program on Tuesday, December 1, 2009. The ... London. ,, Henry Schein,s presentation is sch...
    Breaking Medicine Technology:PFC Pharma Joins DATATRAK's CRO Connect Program 2PFC Pharma Joins DATATRAK's CRO Connect Program 3PFC Pharma Joins DATATRAK's CRO Connect Program 4SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 2SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 3SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 4Henry Schein to Present at the NASDAQ OMX 23rd Investor Program 2Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace 6514 1Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace 6514 2Infinite Mind Announces the Launch of a New Online Vision Therapy Program eyeQ 6512 1Infinite Mind Announces the Launch of a New Online Vision Therapy Program eyeQ 6512 2New Report Shows 97 Medicines and Vaccines Currently in Development for HIV AIDS 6510 1New Report Shows 97 Medicines and Vaccines Currently in Development for HIV AIDS 6510 2New Report Shows 97 Medicines and Vaccines Currently in Development for HIV AIDS 6510 3
    ...ec. 21 A new brain imaging,study by researchers i...Pennsylvania shows that cigarette cravings in smok...ncreased activation in specific regions of the,bra...flow developed by John,Detre, MD, associate profes...to show how abstinence from nicotine produces brai...
    ...c. 21 Romark Laboratories, L.C., a,privately-owne...ng of an,$18 million institutional financing with ...ncing will enable Romark to advance,development of...t of,hepatitis C, and advance its next-generation ...patitis B and C and other viral diseases. Romark i...
    Other Medicine Technology:'Brain Signature' for Cigarette Cravings Identified 2'Brain Signature' for Cigarette Cravings Identified 3
    Fast-Cath Hemostasis Introducers
    Bx Velocity Rx with Hepacoat
    EPT-1000 XP Cardiac Ablation System
    Irrigating Cannula Handpiece (Titanium)
    Medicine Products: